ArticleBiopreservation and biobanking2026
Current Assessment of Existing Biospecimen Use in Population-Based Cancer Research.
Article in Biopreservation and biobanking, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionBiospecimens are an important part of conducting population-based research as they allow the linkage of biological information to other important clinical, social, and environmental factors, providing a more robust understanding of cancer prevention, treatment, and care options. It can be costly and labor-intensive to collect and process these biospecimens, making the use of preexisting, banked biospecimens an appealing option for researchers.
objectiveThis study examines the use of existing biospecimens in National Cancer Institute (NCI)-funded population-based cancer control research grants managed by the Division of Cancer Control and Population Sciences (DCCPS) as of January 2024.
methodsA total of 104 grants managed by DCCPS, NCI that involved the use of existing biospecimens were included in this analysis. Information that was abstracted from the grants included cancer type, biospecimen type, study design (intervention or observational), cancer continuum category (risk/etiology or survivorship), and named biospecimen resource.
resultsThe most commonly used biospecimens were blood products (64.4%), DNA (59.6%), tissue (53.8%), and RNA (26.9%). Risk-focused studies mainly used blood products, while survivorship studies favored tissue and RNA. There was also a notable difference in biospecimen use between studies of common versus rare cancers, with rare cancer studies using tissue and RNA samples less frequently than studies of common cancers.
conclusionThe variety of biospecimen types being used to examine a breadth of hypotheses related to cancer risk and survivorship emphasizes the value of biospecimen resources across the cancer continuum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.